

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Sandercock Brett</u> (Last) (First) (Middle) <u>17 GUINEVIERE COURT</u> (Street) <u>CASTLE HILL, NSW C3 2154</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/01/2005</u>	3. Issuer Name and Ticker or Trading Symbol <u>RESMED INC [RMD]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>ResMed Common Stock</u>	<u>170.86</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>ResMed Options</u>	<u>10/02/1999⁽¹⁾</u>	<u>10/01/2008</u>	<u>ResMed Common Stock</u>	<u>6,000⁽¹⁾⁽²⁾</u>	<u>5.625⁽²⁾</u>	<u>D</u>	
<u>ResMed Options</u>	<u>07/30/2000⁽¹⁾</u>	<u>07/29/2009</u>	<u>ResMed Common Stock</u>	<u>8,000⁽¹⁾⁽²⁾</u>	<u>6.6718⁽²⁾</u>	<u>D</u>	
<u>ResMed Options</u>	<u>07/02/2002⁽¹⁾</u>	<u>07/01/2011</u>	<u>ResMed Common Stock</u>	<u>4,000⁽¹⁾⁽²⁾</u>	<u>25.275⁽²⁾</u>	<u>D</u>	
<u>ResMed Options</u>	<u>01/15/2005⁽¹⁾</u>	<u>01/14/2014</u>	<u>ResMed Common Stock</u>	<u>12,000⁽¹⁾⁽²⁾</u>	<u>20.54⁽²⁾</u>	<u>D</u>	
<u>ResMed Options</u>	<u>01/20/2006⁽¹⁾</u>	<u>01/19/2015</u>	<u>ResMed Common Stock</u>	<u>24,000⁽¹⁾⁽²⁾</u>	<u>24.935⁽²⁾</u>	<u>D</u>	
<u>ResMed Options</u>	<u>12/01/2006⁽³⁾</u>	<u>11/30/2015</u>	<u>ResMed Common Stock</u>	<u>10,000⁽³⁾</u>	<u>40.8</u>	<u>D</u>	

Explanation of Responses:

1. Options are exercisable 1/3 each year beginning 1 year after date of grant.

2. All figures reflect 2-for-1 stock split effective 9/30/2005

3. Options vest 1/4 each year beginning 1 year after date of grant.

Remarks:Brett Sandercock

** Signature of Reporting Person

12/08/2005

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.